Document Detail


Danshen extracts decrease blood C reactive protein and prevent ischemic stroke recurrence: a controlled pilot study.
MedLine Citation:
PMID:  19449344     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The efficacy of a danshen (Salvia miltiorrhiza) dripping pill (DDP) for secondary stroke prevention was evaluated in patients with ischemic cerebrovascular disease. The preparation also contained Panax notoginseng (sanqi) and Dryobalanops camphor. Patients who had suffered from ischemic stroke or a transient ischemic attack (TIA) within the previous 20 days were managed according to established guidelines, and were divided into groups to receive either DDP or non-DDP treatment according to their time of enrolment. Mortality, cerebrovascular events and any suspected adverse reactions during the 1-year follow-up were recorded and analysed. Hematological and hemorheological parameters were measured at the start of the study (baseline) and the end of the follow-up period. A total of 106 patients with ischemic stroke/TIA were enrolled, of which 52 were allocated to take DDP and 54 were in the control group. Recurrent stroke/TIA was observed in five patients (9.6%) with DDP and in 13 patients (24.1%) without DDP during the follow-up. Recurrence in the patient group taking DDP was lower than that in the control group (p<0.05). No significant differences in intracranial hemorrhage and mortality were detected between groups (p>0.05). Blood C reactive protein decreased significantly in patients with DDP compared with patients without DDP. These results indicate that DDP treatment may reduce the risk for stroke/TIA recurrence, and this reduction of risk may be associated with its antiinflammatory effects.
Authors:
Gelin Xu; Wenxin Zhao; Zhiming Zhou; Renliang Zhang; Wusheng Zhu; Xinfeng Liu
Related Documents :
24674734 - Uncemented total hip arthroplasty using a tapered femoral component in obese patients: ...
23297394 - Weight-loss history as a predictor of obesity treatment outcome: prospective, long-term...
20303694 - Open surgery remains a valid option for the treatment of recurrent carotid stenosis.
20055244 - Development of postoperative internal carotid artery occlusion due to the presence of r...
19170854 - Evaluation of patient expectations and treatment satisfaction after 1-year tadalafil th...
16049894 - Assessment of the efficacy of nonablative long-pulsed 1064-nm nd:yag laser treatment of...
Publication Detail:
Type:  Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Phytotherapy research : PTR     Volume:  23     ISSN:  1099-1573     ISO Abbreviation:  Phytother Res     Publication Date:  2009 Dec 
Date Detail:
Created Date:  2009-12-02     Completed Date:  2010-01-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8904486     Medline TA:  Phytother Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  1721-5     Citation Subset:  IM    
Copyright Information:
Copyright (c) 2009 John Wiley & Sons, Ltd.
Affiliation:
Department of Neurology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu Province, China. gelinxu@gmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
C-Reactive Protein / drug effects*
Female
Humans
Ischemic Attack, Transient / drug therapy,  prevention & control*
Kaplan-Meiers Estimate
Male
Middle Aged
Phytotherapy*
Pilot Projects
Recurrence / prevention & control
Salvia miltiorrhiza
Stroke / drug therapy,  prevention & control*
Chemical
Reg. No./Substance:
9007-41-4/C-Reactive Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Toll-like receptor 4-mediated immunoregulation by the aqueous extract of Mori Fructus.
Next Document:  A facile method for reversibly linking a recombinant protein to DNA.